Tanner M Johanns
Washington University School of Medicine · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tanner M Johanns as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:45 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07392957 · Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent GlioblastomaWashington University School of Medicine · recruiting · Glioblastoma · principal investigator
- Ph1NCT05743595 · Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaWashington University School of Medicine · active not recruiting · Unmethylated Glioblastoma · principal investigator
- Ph1/Ph2NCT04557956 · Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentNational Cancer Institute (NCI) · active not recruiting · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma · principal investigator
- Ph1NCT04015700 · Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated GlioblastomaWashington University School of Medicine · active not recruiting · Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT04557956
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2014 to 2019Named on NCT04557956
- Targeting Neoantigens in GlioblastomaR01NS112712 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Gavin Peter Dunn · fiscal years 2019 to 2024Named on NCT04015700
Most cited trial papers
Clinical-trial papers with this author name in glioma, ranked by citations from NIH iCite, fetched 2026-11-12 12:45 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- A Phase 1/2 Study of Disulfiram and Copper With Concurrent Radiation Therapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma.Int J Radiat Oncol Biol Phys · 202435 citationsRCR 4.3
- Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial.Nat Cancer · 20265 citationsRCR 2.5